Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 5Not yet recruiting 3Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Genitourinary 1

Conditions

Oligoprogressive 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 117Carboplatin 47Nivolumab 46Paclitaxel 34Cyclophosphamide 34Cisplatin 33Gemcitabine 30atezolizumab 28Specimen Handling 26venetoclax 25Magnetic Resonance Spectroscopy 25Docetaxel 24fludarabine 23Pemetrexed 23Radiotherapy 22Biopsy 22Bevacizumab 22Ipilimumab 21Azacitidine 21Dexamethasone 19durvalumab 18Radiosurgery 18Fluorouracil 17Cetuximab 16Trastuzumab 15fludarabine phosphate 14Leucovorin 14Cytarabine 14tislelizumab 13Lenalidomide 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × DEAE-Dextran × 1 year × Clear all
NCT05846659 2026-05-15

Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies

ImmuneSensor Therapeutics Inc.

Phase 2 Terminated
16 enrolled 13 charts

Oligoprogressive

NCT05846646 2025-10-20

Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC

ImmuneSensor Therapeutics Inc.

Phase 2 Terminated
6 enrolled 7 charts
GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡